Abba3 Human Antibody for H. pylori BabA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating Helicobacter pylori infections, particularly those targeting the BabA antigen, face challenges due to low immune activity in the gastrointestinal tract and the high recombination rate of H. pylori, which complicates active vaccination and the effectiveness of passive immunization therapies.
Innovation Solution
Development of a fully human immunoglobulin, Abba3, specifically designed to bind to the BabA antigen, which is produced using phage display technology from peripheral blood lymphocytes of infected patients, allowing for effective passive vaccination and detection of H. pylori in fecal samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If active vaccination is used against H. pylori, then immune response is stimulated, but low immune activity in the gastrointestinal tract reduces effectiveness
Solution Approach 1:
Instead of attempting to stimulate immune response in the difficult gastrointestinal environment (active vaccination), the invention inverts the approach by administering pre-formed antibodies (passive immunization) that already possess the required binding activity, bypassing the need for local immune activation
2Reliability
If passive immunization with animal-derived antibodies is used, then neutralization of H. pylori is achieved, but high immunogenicity causes adverse immune reactions
Solution Approach 1:
The invention changes the key parameter of antibody origin from animal-derived to human-derived (fully human immunoglobulin Abba3), which maintains the neutralization effectiveness against H. pylori while dramatically reducing the immunogenicity and associated adverse immune reactions
3Adaptability or versatility
If polyclonal antibodies are used for detection, then broad recognition is achieved, but low specificity reduces diagnostic accuracy
Solution Approach 1:
The invention applies local quality by designing a monoclonal antibody (Abba3) that targets a specific epitope on the BabA adhesin with high precision, rather than using polyclonal antibodies that broadly recognize multiple antigens. This localized specificity at the epitope level achieves both accurate detection and the ability to distinguish BabA-positive strains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Abba3 antibodies effectively neutralize H. pylori by preventing adherence to the gastric mucosa, offering a promising solution for preventing and treating infections with reduced immunogenicity and improved efficacy compared to animal-derived antibodies.
Implementation Method 1
Abba3 is a monoclonal human immunoglobulin of the IgG1 isotype that binds to the BabA adhesin
Data Source
AI summary
The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by Helicobacter pylori (H. pylori). More specifically the present invention relates to new specific variable antibody regions, derivatives thereof and the fully human immunoglobulin, Abba3, which exhibit specific activity to the BabA antigen, expressed by H. pylori, methods for the production of said immunoglobulins, their isolation and use, for example in detection of disease causing H. pylori. The present invention also relates to immunization therapies, i.e. passive vaccination for the treatment and prevention of pathologic infections caused by H. pylori strains.